SURMOUNT-1 Trial: A Plain-English Overview of What It Established

At a glance

| Parameter | Detail | |-----------|--------| | N | 2,539 participants | | Intervention | Tirzepatide 5 mg, 10 mg, or 15 mg subcutaneous injection once weekly | | Comparator | Matching placebo injection once weekly | | Duration | 72 weeks (including 20-week dose escalation) | | Primary endpoint | Percentage change in body weight from baseline to week 72 | | Key result | −15.0% (5 mg), −19.5% (10 mg), −20.9% (15 mg) vs −3.1% (placebo) | | Registration | NCT04184622 |

The Question SURMOUNT-1 Asked

Before 2022, no anti-obesity drug had reliably produced weight loss exceeding 15% in a large randomized trial. Semaglutide 2.4 mg (Wegovy) had reached approximately 14.9% at 68 weeks in STEP 1, which was itself a significant advance. Tirzepatide was already approved for type 2 diabetes under the brand name Mounjaro, where it showed pronounced weight reduction as a secondary outcome. The SURMOUNT program was designed to test whether those weight effects would hold up as a primary endpoint in people without diabetes.

SURMOUNT-1 asked a simple question: in adults with obesity or overweight plus at least one comorbidity, does once-weekly tirzepatide at three different dose levels reduce body weight significantly more than placebo over 72 weeks?

Who Was Enrolled

The trial recruited adults aged 18 and older with a BMI of 30 or greater, or a BMI of 27 or greater with at least one weight-related condition (hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease). People with type 2 diabetes were excluded, which is a critical design choice. This population represents adults who would seek anti-obesity pharmacotherapy in a general endocrinology or primary care setting.

Key baseline characteristics across groups:

| Characteristic | Mean value | |----------------|------------| | Age | ~45 years | | Body weight | ~104.8 kg | | BMI | ~38.0 kg/m² | | Female | ~67.5% | | White | ~70.5% |

The trial enrolled participants across 119 sites in 9 countries (Argentina, Brazil, China, India, Japan, Mexico, Russia, Taiwan, United States). About 14% of participants were from the United States. This multinational composition is worth noting because obesity prevalence, dietary patterns, and healthcare access differ across these regions.

What Participants Were Given

Randomization was 1:1:1:1 to tirzepatide 5 mg, 10 mg, 15 mg, or placebo. All injections were subcutaneous, once weekly, using the same delivery device regardless of group.

The dose escalation schedule is clinically relevant. No one started at their target dose. All participants in the 10 mg and 15 mg groups began at 2.5 mg weekly for four weeks, then increased by 2.5 mg every four weeks until reaching their assigned dose. This 20-week titration period was designed to reduce gastrointestinal side effects, which are the most common reason patients discontinue GLP-1 class drugs.

All participants received lifestyle counseling: a 500 kcal/day deficit diet and at least 150 minutes per week of physical activity. The placebo group received the same counseling, meaning the 3.1% weight loss seen with placebo reflects the effect of caloric restriction and exercise advice alone.

What Was Measured and How

The trial had two co-primary endpoints:

1. Percentage change in body weight from baseline to week 72
2. Proportion of participants achieving ≥5% weight loss at week 72

Both were assessed using two different statistical frameworks simultaneously (called "estimands"). The treatment-policy estimand included all randomized participants regardless of whether they completed the study or stayed on medication. The efficacy estimand evaluated only the effect while participants were actually receiving treatment. This dual-analysis approach is important because the treatment-policy analysis penalizes a drug if patients drop out, while the efficacy estimand shows what the drug does when actually taken.

Body weight was measured at clinic visits scheduled every 4 weeks for the first 24 weeks, then every 8 weeks until week 72.

The Results in Detail

Weight Loss by Dose (Treatment-Policy Estimand)

| Group | Mean % change | Difference vs placebo | P value | |-------|--------------|----------------------|---------| | Tirzepatide 5 mg | −15.0% | −11.9% | <0.001 | | Tirzepatide 10 mg | −19.5% | −16.4% | <0.001 | | Tirzepatide 15 mg | −20.9% | −17.8% | <0.001 | | Placebo | −3.1% |, |, |

Categorical Weight Loss Thresholds (Treatment-Policy Estimand)

| Threshold | 5 mg | 10 mg | 15 mg | Placebo | |-----------|------|-------|-------|---------| | ≥5% loss | 85% | 89% | 91% | 35% | | ≥10% loss | 69% | 78% | 84% | 19% | | ≥15% loss | 50% | 67% | 73% | 10% | | ≥20% loss | 32% | 50% | 57% | 3% | | ≥25% loss | 16% | 30% | 36% | 1.5% |

These categorical results tell a story the mean percentages cannot. At the highest dose, more than half of all participants lost at least 20% of their body weight. One in three lost 25% or more. These are weight reductions that previously required bariatric surgery.

Absolute Weight Lost

Mean baseline weight was approximately 104.8 kg. At 15 mg, participants lost a mean of approximately 22 kg (roughly 48 pounds). At 5 mg, the mean loss was approximately 16 kg (roughly 35 pounds).

Cardiometabolic Secondary Outcomes

Tirzepatide also improved waist circumference (reductions of 14.5 cm at 15 mg vs 3.4 cm for placebo), systolic blood pressure, fasting insulin, and lipid profiles. These secondary outcomes suggest the weight loss translated into meaningful metabolic improvement beyond the number on the scale.

Safety and Tolerability

The most common adverse events were gastrointestinal: nausea, diarrhea, constipation, and vomiting. These occurred primarily during the dose-escalation phase and tended to diminish over time.

| Event | 5 mg | 10 mg | 15 mg | Placebo | |-------|------|-------|-------|---------| | Nausea | 24.6% | 33.3% | 31.0% | 9.5% | | Diarrhea | 18.7% | 21.2% | 16.4% | 7.3% | | Constipation | 17.1% | 17.2% | 11.7% | 4.8% | | Vomiting | 5.7% | 9.1% | 12.2% | 1.7% |

Discontinuation due to adverse events was 4.3% (5 mg), 7.1% (10 mg), 6.2% (15 mg), and 2.6% (placebo). These rates are moderate, though the 20-week titration schedule likely mitigated what would have been higher GI intolerance at full doses.

Serious adverse events occurred at similar rates across all groups (roughly 5-7%). There were no confirmed cases of pancreatitis. Cholelithiasis (gallstones) occurred more frequently in tirzepatide groups, consistent with rapid weight loss from any cause.

Limitations the Authors Acknowledged

The investigators were transparent about several constraints:

Duration. 72 weeks is long for a drug trial but short for a chronic disease. Obesity is a lifelong condition, and this study cannot tell us what happens at year 3, 5, or 10. The SURMOUNT-4 extension later showed that weight regain occurs after discontinuation, confirming that tirzepatide requires ongoing use.

Population. The exclusion of type 2 diabetes limits generalizability. SURMOUNT-2 addressed this gap, but SURMOUNT-1 cannot be directly applied to patients with diabetes.

Diversity. While multinational, the cohort was approximately 70% White. The study was not powered to detect differential efficacy across racial or ethnic subgroups.

Lifestyle intervention. All groups received diet and exercise counseling. In real-world practice, adherence to lifestyle modification varies enormously. The placebo group's 3.1% loss may overestimate what patients achieve without structured support.

Comparator. The study used placebo, not an active comparator. Head-to-head data against semaglutide 2.4 mg did not exist at the time. Indirect comparisons across trials (STEP 1 vs SURMOUNT-1) are unreliable due to different populations and protocols.

What This Means for Clinical Practice Today

SURMOUNT-1 established tirzepatide as the most effective pharmaceutical weight-loss agent studied in a large phase 3 trial at publication. The FDA approved tirzepatide for chronic weight management in November 2023 under the brand name Zepbound.

Several practical implications stand out:

Dose selection matters. The gap between 5 mg and 15 mg is roughly 6 percentage points of body weight. A 100 kg patient choosing 5 mg over 15 mg might expect about 6 fewer kilograms of loss. Clinicians must weigh this against the higher GI side-effect burden at escalated doses.

The 20-week ramp matters. Patients should expect limited weight loss during early titration. Clinicians setting expectations around timelines should account for this slow start.

Weight regain after stopping is expected. SURMOUNT-1 was not a discontinuation study, but subsequent data from SURMOUNT-4 confirmed that stopping tirzepatide leads to substantial weight regain. Payers and patients need to plan for indefinite treatment.

Bariatric surgery comparisons. Mean weight loss of 20.9% at 15 mg approaches outcomes seen with sleeve gastrectomy (typically 20-25% at one year) and laparoscopic gastric banding. It remains below Roux-en-Y gastric bypass (30-35%). For patients who are not surgical candidates or prefer pharmacotherapy, tirzepatide represents a meaningful alternative.

The American Gastroenterological Association's 2024 clinical practice guideline now recommends tirzepatide as a first-line pharmacotherapy option for obesity, citing SURMOUNT-1 as key evidence.

How SURMOUNT-1 Fits in the Broader Program

SURMOUNT-1 was the first of four phase 3 trials:

• SURMOUNT-1: Obesity without diabetes (this trial)
• SURMOUNT-2: Obesity with type 2 diabetes
• SURMOUNT-3: Tirzepatide after 12-week intensive lifestyle intervention
• SURMOUNT-4: Randomized withdrawal (treated all, then randomized to continue vs switch to placebo)

Together, these trials established the evidence base that led to Zepbound's approval and shaped current prescribing guidelines for tirzepatide in weight management.

Frequently asked questions

›

›

›

›

›

›

›

›

›

›

References

1. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205-216. PubMed
2. Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021;384(11):989-1002. PubMed
3. Aronne LJ, Sattar N, Horn DB, et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity (SURMOUNT-4). JAMA. 2024;331(1):38-48. PubMed
4. Zepbound (tirzepatide) prescribing information. US Food and Drug Administration. 2023. FDA Label
5. Velazquez A, Apovian CM, et al. Pharmacologic treatment of obesity: AGA clinical practice guideline. Gastroenterology. 2024;166(1):62-93. PubMed